Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06761898 · ClinicalTrials.gov registry record · Phase 1
A Study of Different Forms of BGB-43395 and Food Effect in Healthy Participants
A Phase 1 study, sponsored by BeiGene.
- Completed
- Registry status
- Phase 1
- Development phase
- 51
- Enrollment target
NCT06761898 is a Phase 1 study that has completed, run by BeiGene. The registered enrollment target is 51 participants.
The verdict
NCT06761898, a Phase 1 study, has completed, sponsored by BeiGene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 51 participants
- Enrollment target
Study Summary
Study to determine the relative bioavailability of BGB-43395 solid dispersion tablet compared to salt tablet in healthy adult participants in Part 1 and the effect of food on the selected BGB-43395 formulation solid dispersion tablet or salt tablet in healthy adult participants in Part 2.
Interventions
- DRUG BGB-43395
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2025-01-14 |
| Est. Completion | 2025-05-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06761898
The ClinicalTrials.gov registry entry for NCT06761898 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BeiGene, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BGB-43395 is the first listed.
NCT06761898 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06761898 about?
NCT06761898 is a clinical study titled "A Study of Different Forms of BGB-43395 and Food Effect in Healthy Participants". Study to determine the relative bioavailability of BGB-43395 solid dispersion tablet compared to salt tablet in healthy adult participants in Part 1 and the effect of food on the selected BGB-43395 formulation solid dispersion tablet or salt tablet in healthy adult participants in Part 2.
What is the current status of trial NCT06761898?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 51 participants. The study started on 2025-01-14. Estimated completion is 2025-05-20.
What interventions are being tested in trial NCT06761898?
The interventions under investigation include: BGB-43395 (DRUG).
Who is sponsoring clinical trial NCT06761898?
This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.